Maharashtra Food and Drugs Administration (FDA) on Sunday restricted the sale, distribution, and use of Coldrif syrup, Batch no SR 13, with immediate effect. Those who are in possession have been instructed to report it to the Drug Control Authorities. According to the public alert, the ban has been imposed due to toxic adulteration.
The press release noted, “The Food and Drug Administration, Maharashtra, has been alerted to reports of the tragic deaths of children in Madhya Pradesh and Rajasthan, Coldrif Syrup (Phenylephrine Hydrochloride, Chlorpheniramine Maleate Syrup), Batch No. SR-13, Mfg. Dt. May-2025, Exp. Dt. April 2027, manufactured by Sresan Pharma, Sunguvarchathiram, Kancheepuram District, Tamil Nadu, which has been allegedly adulterated with Diethylene Glycol (DEG), a toxic substance.”
Maharashtra FDA restricts sale, distribution and use of Coldrif syrup Batch no SR 13 with immediate effect. Those who are possession, have been instructed to report it to Drug Control Authorities pic.twitter.com/YrSHJMjE3A
— ANI (@ANI) October 5, 2025
---Advertisement---
The Maharashtra FDA has urged all licensees and the public to immediately halt the sale, distribution, and use of the cough syrup. The public may report possession of the said drug on the toll-free number 1800222365, or send an email to jchq.fda-mah@nic.in or ph-9892832289.
The FDA officials are constantly in communication with Tamil Nadu DCA authorities to track the distribution of the said product batch to Maharashtra. All Drug Inspectors and Assistant Commissioners have been directed to alert retailers, wholesalers, and hospitals to suspend the supply and stock of said product batch.
